News
22 Feb - 25 Feb 2009:Proxy Biomedical Limited to Exhibit at the 55th Annual Meeting of the Orthopaedic Research Society in Las Vegas
Proxy Biomedical Limited will be exhibiting at the upcoming 55th Annual Meeting of the Orthopaedic Research Society in Las Vegas, Nevada. If you
would be interested in meeting one of our team, please get in touch with us at info@proxybiomedical.com.
8 Dec 2008:Proxy Biomedical Limited Select Cleveland for US Headquarters
Proxy Biomedical Limited was granted Job Creation Tax Credits today by the State of Ohio.
Pending additional grant approvals, the company will invest $1.5 million in capital, and $1.8 million in annual payroll to establish 26 highly paid jobs in Cleveland beginning January, 2009. This announcement affirms a trend of leading biomedical firms recently establishing US Headquarters in the Northeast Ohio region.
The new Cleveland Proxy Biomedical facility will be a full service operation that designs, develops, manufactures and markets biomaterials for the repair and regeneration of tissue for advanced surgical procedures. The operation will serve as both a market development site for new product platforms, and a US Headquarters.
Proxy Biomedical also considered other regions with strong life science clusters for this expansion, but ultimately chose Northeast Ohio because of the region's leading healthcare and educational institutions, such as the Cleveland Clinic and University Hospitals, and because of the State of Ohio's strong commitment to the biomedical industry. "Access to partners, customers and workforce is critical to Proxy Biomedical's success," says Peter Gingras, Proxy Biomedical CEO. "Establishing US Operations in Northeast Ohio will allow us to take advantage of critical product development support and clinical trials that will enable our accelerated growth and service to the world's largest market, the United States." Proxy has already developed strategic partnerships with a Dayton, Ohio firm, Case Western Reserve University, The Cleveland Clinic, and the Global Cardiovascular Innovation Center (GCIC). The new facility will provide a suite of wound coverings and biologic scaffold to support Cardiology, Urology, Gynecology, Colorectal, and Orthopedic surgical procedures.
8 Oct 2008: Article Published in Medical Device Developments!
Proxy Biomedical have published the article, "Biomaterial Customisation" in this months publication of
Medical Device Developments.
Download a copy of the article here.
11 Sep 2008-13 Sep 2008: SFB Meeting on Translational Research
Proxy Biomedical will have a stand at the Society for Biomaterials 3 day symposium, being held in Atlanta (Buckhead), Georgia this year.
To improve the lives of patients, scientific research must have practical applications. Discoveries made at “the bench” must ultimately find their way to the patient's “bedside.”
The symposium will focus not only on expediting this process, but also on the new and emerging technologies in the biomaterials field that are currently in the midst of such translation.
Click here for more information>>
21 Aug 2008 New Facility Official Opening!
Today we officially opened our new manufacturing premises in an Údarás na Gaeltachta facility in Spiddal (An Spidéal), Co. Galway. With support from Údarás na Gaeltachta, the new facility will house all the services offered by Proxy, which include the design, development, manufacturing, sales and distribution of next generation medical devices and biomaterials for the repair and regeneration of tissue. The provision of all services from one facility is unique in the sector.
Peter Mulrooney, Director, Operations of Proxy Biomedical, outlined the benefits of the new facility. "Proxy Biomedical has been placing significant time and resources in developing a portfolio of platform biomaterial technologies for the expanding field of tissue engineering. We hope to partner with companies in Ireland and other countries with strong life science clusters. The new facility will provide growth potential and added capacity for existing and new customers going forward."
Minister Éamon Ó Cuív, officially opened the facility. Pádraig Ó hAoláin, CEO of Údarás na Gaeltachta, commented, "We are very pleased to be able to facilitate and support the expansion of Proxy Biomedical to the Connemara Gaeltacht."
28 May 2008- 1 June 2008 Attending the WBC in Amsterdam!
From the 28th May until the 1st June, Proxy Biomedical will exhibit at the World Biomaterials Congress held in Amsterdam. It will be an opportunity for you to talk to our MD, Peter Gingras, our Director of Operations, Peter Mulrooney, and a perfect chance to view the various exciting products that we research, design and manufacture. Top of the list is our MotifMESH Tissue Engineering Biomaterial which is a product that can be customised to suit your needs, a biomaterial for guided tissue regeneration. Check out our product pages for more information on what to keep an eye out for.
15 Jan 2008 New website launched!
We are pleased to announce the launch of our new website! We encourage you to take a look around to see what has changed.
15 Jan 2008 New facility in Co. Galway
Proxy Biomedical has recently moved into a purpose built 10,000 sq.
ft medical device facility with a 3,000 sq. ft. cleanroom
in County Galway, Ireland.
17 Sep 2007 Proxy Biomedical Signs Distribution Agreement for Inclusion of CryoLife BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
ATLANTA, Ga., Sept. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has signed a distribution agreement allowing Proxy Biomedical Limited to include CryoLife's BioGlue(R) Surgical Adhesive into a hernia repair kit. In addition to BioGlue, the kit includes a surgical mesh from Proxy Biomedical's line of proprietary synthetic polymer surgical meshes. Initially, Proxy Biomedical will distribute the kits in Ireland, the United Kingdom and Germany.
"Hernia repair is one of the most commonly performed surgical procedures worldwide. BioGlue is already approved for this particular indication in international markets, and we believe that BioGlue, coupled with Proxy Biomedical's proprietary meshes, will give surgeons a unique option for the repair of hernia and other fascial defects," stated Steven G. Anderson, president and chief executive officer of CryoLife, Inc.
"We believe that BioGlue provides a highly competitive method for atraumatic surgical mesh fixation. BioGlue has been used effectively for several surgical procedures, and we look forward to providing the product in kit form with our series of next generation surgical mesh products. BioGlue offers a simple and effective solution for surgical mesh fixation with enhanced procedural value," stated Peter Gingras, managing director of Proxy Biomedical Limited.
Currently, the most common methods of hernia mesh fixation include sutures and tacking systems. Between 10 and 20 percent of patients complain of pain resulting from hernia repair, most often associated with the fixation method. It is anticipated that the use of BioGlue, as an adjunct to sutures and tacking systems, will help minimize this incidence of postoperative pain.
BioGlue is distributed directly by CryoLife Europa in the UK and Germany for all types of soft tissue repair, including in cardiac, neuro and general surgery. In Ireland, the product is distributed through a distributor for the same indications.
About BioGlue BioGlue is a two-component adhesive that creates a flexible, mechanical seal, independent of the body's clotting mechanism, within 20 to 30 seconds, and reaches its maximum bonding strength in two to three minutes. It is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels, and is CE-marked in the European Community. In addition, BioGlue is approved in Canada for use in soft tissue repair and in Australia for use in vascular and pulmonary sealing and repair.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. For additional information about CryoLife please visit http://www.cryolife.com.
About Proxy Biomedical Limited
Founded in 2002, Proxy Biomedical Limited, located in Galway, Ireland, is a privately held, life science company engaged in commercializing proprietary biomaterials for the repair and regeneration of tissue. Proxy Biomedical's proprietary surgical mesh products include MotifMesh, VitaMesh, MotifMesh MIDS, and VitaMesh MIDS, which are CE marked for distribution within the European Community and FDA approved for distribution within the United States.
SOURCE CryoLife, Inc.
Corporate brochure
Download our corporate brochure for details on the company including our markets, our capabilities, product development cycle and product portfolio.
Our products
